This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

ZIOPHARM Presents Preclinical Data Supporting DNA-Based IL-12 Therapy For Breast Cancer

NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of results from a study in a breast cancer murine model demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12, a viral vector DNA-based therapeutic for the controlled, local expression of IL-12, an important protein for enhancing antitumor immunity. The data were presented at the American Association for Cancer Research 2013 Annual Meeting (AACR 2013) taking place April 6-10, 2013 in Washington, D.C. The study was conducted jointly by ZIOPHARM and Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function. ZIOPHARM is Intrexon's exclusive channel partner for the development of in vivo therapeutics in oncology.

For the study, intratumoral administration of Ad-RTS-mIL-12 (Ad) was examined in a 4T1 BALB/c mouse breast carcinoma model. Production of murine IL-12 was controlled using Intrexon's RheoSwitch Therapeutic System ® (RTS ®) platform and oral administration of the activator ligand INXN-1001 (AL). Oral administration of AL was found to elicit a dose-related increase in plasma AL levels, which correlated with increasing tumor levels of AL. The increase in tumor AL levels in combination with Ad in turn resulted in a dose-related increase in expression of mIL-12 in the tumor, with minimal increase in serum mIL-12. This increase in AL-regulated tumor IL-12 levels correlated with an increase in tumor-infiltrating CD4 + and CD8 + T cells in and adjacent to the tumor, concomitant with a decrease in tumor regulatory T cells. This resulted in a dose-related decrease in tumor growth rate. Moreover, the therapeutic strategy appears to be well tolerated, as no change in clinical signs or body weight was observed in the treated animals when compared with vehicle alone. 

Samuel Broder, M.D., Chairman of Intrexon's Therapeutic Opportunities Committee and former Director of the NCI (National Cancer Institute), stated, "Two major obstacles for the development of immunotherapeutics in the treatment of cancer are the ability of tumors to evade the anti-cancer capabilities of the immune system and the toxicity often associated with the systemic administration of immunomodulating agents. To overcome these challenges, we have developed Ad-RTS-IL-12, a DNA-based system for the regulated expression of IL-12, that allows for localized, controlled expression of immunomodulating cytokines and activation of their corresponding anti-tumor effects. This strategy is now being tested in the clinic, with the recent launch of a Phase 2 Study of Ad-RTS-IL-12 combined with palifosfamide in the treatment of advanced breast cancer."

Stock quotes in this article: ZIOP 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs